NCT04865744

The Effect of Semaglutide on Pituitary Function

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Tartu · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7 mg on growth hormone secretion.

Detailed description

The randomized blinded placebo-controlled clinical trial is conducted on 10 healthy volunteers. 5 study subjects receive once 7 mg of oral semaglutide and once placebo. 5 study subjects receive once 14 mg of oral semaglutide and once placebo. The study group and order of administration of study medication are decided on randomization. The placebo and oral semaglutide are administered at least 4 weeks apart. Blood samples are taken before and during 4 hours after the study medication administration (at 60, 90, 120, 150, 180, and 240 minutes after study medication administration). The primary endpoint is the peak value of growth hormone measured during the 4 hours after study medication administration.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Semaglutide 7 MG Oral Tablet	Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.
DRUG	Placebo	Placebo tablet is taken after an overnight fast with up to120 ml of water.
DRUG	Semaglutide 14 MG Oral Tablet	Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.

Timeline

• Start date: 2021-05-19
• Primary completion: 2021-09-23
• Completion: 2021-09-30
• First posted: 2021-04-29
• Last updated: 2023-02-22

Locations

1 site across 1 country: Estonia